% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • risingedge77 risingedge77 May 15, 2014 7:31 PM Flag

    Will Lewis mentions MDR-TB at today's conference

    While discussing slide 15, Resourcing for Success / Launch / Commercialization, Clinical Studies to Expand Label, Will Lewis said that "drug resistant TB is an example".

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Found this in my reading up on it and go to cdc

      What is multidrug-resistant tuberculosis (MDR TB)?

      Multidrug-resistant TB (MDR TB) is caused by an organism that is resistant to at least isoniazid and rifampin, the two most potent TB drugs. These drugs are used to treat all persons with TB disease.

      What is extensively drug resistant tuberculosis (XDR TB)?

      Extensively drug resistant TB (XDR TB) is a rare type of MDR TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).

      Because XDR TB is resistant to the most potent TB drugs, patients are left with treatment options that are much less effective.

      XDR TB is of special concern for persons with HIV infection or other conditions that can weaken the immune system. These persons are more likely to develop TB disease once they are infected, and also have a higher risk of death once they develop TB.

    • Imagine if their new Chief Medical Officer happens to be a big gun in pulmonology as it relates to pneumonia and TB.

      • 1 Reply to b_leaguered
      • The problem is that nobody employed by Insmed would ever say anything in public which could be interpreted by the FDA as promoting off-label use.

        However .....

        Poster Board 1018: A Randomized, Double-Blind, Placebo-Controlled Study Of Liposomal Amikacin For Inhalation (Arikace®) In Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease, [Publication Number: A4126]

        K.N. Olivier, MD, MPH
        R. Gupta, M.D.
        C.L. Daley, MD
        K.L. Winthrop, MD, MPH
        S. Ruoss, M.D.
        D.J. Addrizzo-Harris, MD
        P. Flume, MD
        D. Dorgan, M.D.
        M.A. Salathe, MD
        B.A. Brown-Elliott, MS, MT (ASCP), SM
        R.J. Wallace, MD
        D.E. Griffith, MD

        Arikace in NTM Study Group.

        Day/Date: Tuesday, May 20, 2014
        Session Time: 8:15 AM - 10:45 AM
        Poster Viewing: 8:15-9:15
        Discussion: 9:15-10:45
        Room: Sapphire Ballroom E-F (Level 4)
        Location: Hilton San Diego Bayfront

    • That was an historic moment - the very first time the Company has publicly acknowledged the potential of Arikayce in the treatment of Tuberculosis.

      There's an informative FDA presentation on the various GAIN fast-track pathways, which implies that a significant proportion of Breakthrough Therapy designations have subsequently been withdrawn because an expedited approval would have outpaced the manufacturing timeline.

      I'm guessing Insmed's projections for the likely demand for the drug under various approval scenarios would have to have factored in off-label use in MDR-TB.

    • FUD was ahead of the curve when he/she asserted that Arikayce could be approved for treatment of MDR-TB

13.82-0.12(-0.86%)9:43 AMEDT